Novo Nordisk A/S (NVO)
124.58
+1.53
(+1.24%)
USD |
NYSE |
May 06, 16:00
124.40
-0.18
(-0.14%)
After-Hours: 20:00
Novo Nordisk Accounts Receivable (Quarterly): 8.245B for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 8.245B |
December 31, 2023 | 9.617B |
September 30, 2023 | 7.450B |
June 30, 2023 | 8.945B |
March 31, 2023 | 7.393B |
December 31, 2022 | 7.277B |
September 30, 2022 | 6.022B |
June 30, 2022 | 5.732B |
March 31, 2022 | 5.438B |
December 31, 2021 | 6.187B |
September 30, 2021 | 4.659B |
June 30, 2021 | 4.176B |
March 31, 2021 | 4.418B |
December 31, 2020 | 4.584B |
September 30, 2020 | 3.841B |
June 30, 2020 | 3.875B |
March 31, 2020 | 4.444B |
December 31, 2019 | 3.735B |
September 30, 2019 | 3.300B |
June 30, 2019 | 3.541B |
March 31, 2019 | 3.229B |
December 31, 2018 | 3.491B |
September 30, 2018 | 2.884B |
June 30, 2018 | 2.943B |
March 31, 2018 | 2.702B |
Date | Value |
---|---|
December 31, 2017 | 3.250B |
September 30, 2017 | 2.722B |
June 30, 2017 | 2.671B |
March 31, 2017 | 2.444B |
December 31, 2016 | 2.877B |
September 30, 2016 | 2.443B |
June 30, 2016 | 2.356B |
March 31, 2016 | 2.509B |
December 31, 2015 | 2.268B |
September 30, 2015 | 2.046B |
June 30, 2015 | 2.136B |
March 31, 2015 | 2.124B |
December 31, 2014 | 2.129B |
September 30, 2014 | 1.843B |
June 30, 2014 | 2.107B |
March 31, 2014 | 1.930B |
December 31, 2013 | 2.019B |
September 30, 2013 | 1.759B |
June 30, 2013 | 1.921B |
March 31, 2013 | 1.818B |
December 31, 2012 | 1.708B |
September 30, 2012 | 1.678B |
June 30, 2012 | 1.661B |
March 31, 2012 | 1.714B |
December 31, 2011 | 1.629B |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
3.300B
Minimum
Sep 2019
9.617B
Maximum
Dec 2023
5.644B
Average
5.048B
Median
Accounts Receivable (Quarterly) Benchmarks
Amgen Inc | 6.776B |
Vertex Pharmaceuticals Inc | 1.563B |
Viking Therapeutics Inc | -- |
Evaxion Biotech AS | -- |
Moderna Inc | 137.00M |